索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]武菲,张英谦.射血分数中间值的心力衰竭研究动向与新视角[J].国际心血管病杂志,2024,02:101-104.
点击复制

射血分数中间值的心力衰竭研究动向与新视角(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年02期
页码:
101-104
栏目:
综述
出版日期:
2024-03-25

文章信息/Info

Title:
-
作者:
武菲; 张英谦
050011 石家庄，河北医科大学研究生院（武菲）；050031 石家庄，河北省儿童医院心内科 河北省小儿心血管重点实验室（张英谦）
Author(s):
-
关键词:
射血分数中间值的心力衰竭; 左室射血分数; 心血管事件
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.02.010
文献标识码:
-
摘要:
射血分数中间值的心力衰竭（HFmrEF）是左室射血分数40%～49%的心力衰竭，其症状轻，漏诊率高。该文探讨HFmrEF的流行病学、临床特征、发病机制、转归及预后，旨在为未来心力衰竭管理提供更全面的认识，以改善患者的预后和生活质量。
Abstract:
-

参考文献/References

[1] Kirk R, Dipchand AI, Rosenthal DN, et al. The international society for heart and lung transplantation guidelines for the management of pediatric heart failure: executive summary[J]. J Heart Lung Transplant, 2014, 33(9):888-909.
[2] Soufer R, Wohlgelernter D, Vita NA, et al. Intact systolic left ventricular function in clinical congestive heart failure[J]. Am J Cardiol, 1985, 55(8):1032-1036.
[3] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). developed with the special contribution of the heart failure association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18(8):891-975.
[4] Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure[J]. Eur J Heart Fail, 2020, 22(8):1342-1356.
[5] Shaddy RE, George AT, Jaecklin T, et al. Systematic literature review on the incidence and prevalence of heart failure in children and adolescents[J]. Pediatr Cardiol, 2018, 39(3):415-436.
[6] Srivastava PK, Hsu JJ, Ziaeian B, et al. Heart failure with mid-range ejection fraction[J]. Curr Heart Fail Rep, 2020, 17(1):1-8.
[7] Raja DC, Samarawickrema I, Das S, et al. Long-term mortality in heart failure with mid-range ejection fraction: systematic review and meta-analysis[J]. ESC heart failure, 2022, 9(6):4088-4099.
[8] Savarese G, Stolfo D, Sinagra G, et al. Heart failure with mid-range or mildly reduced ejection fraction[J]. Nat Rev Cardiol, 2022, 19(2):100-116.
[9] Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry[J]. Eur J Heart Fail, 2017, 19(12):1574-1585.
[10] Kap?on-Cie?licka A, Benson L, Chioncel O, et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction-insights from the ESC-HFA EORP heart failure long-term registry[J]. Eur J Heart Fail, 2022, 24(2):335-350.
[11] Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure[J]. Circulation, 2020, 141(5):352-361.
[12] Streng KW, Nauta JF, Hillege HL, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction[J]. Int J Cardiol, 2018, 271:132-139.
[13] Li P, Zhao H, Zhang J, et al. Similarities and differences between HFmrEF and HFpEF[J]. Front Cardiovasc Med, 2021, 8:678614.
[14] Simmonds SJ, Cuijpers I, Heymans S, et al. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding[J]. Cells, 2020, 9(1):242.
[15] Moliner P, Lupón J, Barallat J, et al. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction[J]. Int J Cardiol, 2018, 257:188-192.
[16] Boulet J, Massie E, Rouleau JL. Heart failure with midrange ejection fraction—what is it, if anything?[J]. Can J Cardiol, 2021, 37(4):585-594.
[17] Brown LAE, Wahab A, Ikongo E, et al. Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction[J]. Eur Heart J Cardiovasc Imaging, 2022, 24(1):38-45.
[18] Huang YT, Zhang K, Jiang MM, et al. Regulation of energy metabolism by combination therapy attenuates cardiac metabolic remodeling in heart failure[J]. Int J Biol Sci, 2020, 16(16):3133-3148.
[19] Haykowsky MJ, Brubaker PH, John JM, et al. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction[J]. J Am Coll Cardiol, 2011, 58(3):265-274.
[20] Savarese G, Vedin O, D'Amario D, et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure[J]. JACC Heart Fail, 2019, 7(4):306-317.
[21] Ueda T, Kawakami RK, Nishida TK, et al. Left ventricular ejection fraction (EF) of 55% as cutoff for late transition from heart failure (HF) with preserved EF to HF with mildly reduced EF[J]. Circ J, 2015, 79(10):2209-2215.
[22] Lupón J, Gavidia-Bovadilla G, Ferrer E, et al. Heart failure with preserved ejection fraction infrequently evolves toward a reduced phenotype in Long-Term survivors[J]. Circ Heart Fail, 2019, 12(3):e005652.
[23] Xiang B, Zhang R, Wu X, et al. Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis[J]. JAMA Netw Open, 2022, 5(9):e2231963.
[24] Wehner GJ, Jing LY, Haggerty CM, et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?[J]. Eur Heart J, 2020, 41(12):1249-1257.
[25] Lund LH, Claggett B, Liu JK, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum[J]. Eur J Heart Fail, 2018, 20(8):1230-1239.
[26] Bartko PE, Hülsmann M, Hung J, et al. Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction[J]. Eur Heart J, 2020, 41(29):2799-2810.
[27] Ghio S, Guazzi M, Scardovi AB, et al. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction[J]. Eur J Heart Fail, 2017, 19(7):873-879.
[28] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC[J]. Rev Esp Cardiol (Engl Ed), 2022, 75(6):523.
[29] Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials[J]. Eur Heart J, 2018, 39(1):26-35.
[30] Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study[J]. Eur J Heart Fail, 2017, 19(10):1258-1269.
[31] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. Circulation, 2022, 145(18):e895-e1032.
[32] Xiang Y, Shi W, Li Z, et al. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials[J]. Medicine(Baltimore), 2019, 98(13):e14967.
[33] McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004.
[34] Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2019, 21(10):1169-1186.
[35] Abraham WT, Kuck KH, Goldsmith RL, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation[J]. JACC Heart Fail, 2018, 6(10):874-883.

备注/Memo

备注/Memo:
基金项目：2023年度河北省医学科学研究课题计划（20231120）
通信作者：张英谦， E-mail：zhangyingqian666@163.com
更新日期/Last Update: 2024-03-25